Atherosclerosis
Volume 205, Issue 1 , Pages 207-213 , July 2009

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance

  • Axel Linke

      Affiliations

    • Heart Center, Department of Cardiology, University of Leipzig, Leipzig, Germany
    • ,
  • Melanie Sonnabend

      Affiliations

    • Heart Center, Department of Cardiology, University of Leipzig, Leipzig, Germany
    • ,
  • Mathias Fasshauer

      Affiliations

    • Department of Internal Medicine III, University of Leipzig, Ph.-Rosenthal-Str. 27, D-04103 Leipzig, Germany
    • ,
  • Robert Höllriegel

      Affiliations

    • Heart Center, Department of Cardiology, University of Leipzig, Leipzig, Germany
    • ,
  • Gerhard Schuler

      Affiliations

    • Heart Center, Department of Cardiology, University of Leipzig, Leipzig, Germany
    • ,
  • Josef Niebauer

      Affiliations

    • Heart Center, Department of Cardiology, University of Leipzig, Leipzig, Germany
    • Institute of Sports Medicine, Paracelsus Private University, Salzburg, Austria
    • ,
  • Michael Stumvoll

      Affiliations

    • Department of Internal Medicine III, University of Leipzig, Ph.-Rosenthal-Str. 27, D-04103 Leipzig, Germany
    • ,
  • Matthias Blüher

      Affiliations

    • Department of Internal Medicine III, University of Leipzig, Ph.-Rosenthal-Str. 27, D-04103 Leipzig, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 341 9715984; fax: +49 341 9722439.

Received 9 April 2008 ,Revised 5 November 2008 ,Accepted 26 November 2008.

References 

  1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15
  2. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995;76:69C–77C
  3. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21:1927–1934
  4. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97.
  6. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82:74U–81U
  7. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O’Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737–743
  8. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  9. Taylor AJ, Sullenberger LE, Hyun YL. ARBITER 3: atherosclerosis regression during open-label continuation of extended-release niacin following ARBITER-2. Abstract 943, AHA Scientific Sessions; 2005.
  10. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism. 2006;55:1283–1285
  11. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2006;
  12. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9:352–355
  13. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115:3634–3640
  14. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54:2911–2916
  15. Blüher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053–3060
  16. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:214–223
  17. Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia. 2002;45:210–216
  18. Karpe F, Frayn KN. The nicotinic acid receptor—a new mechanism for an old drug. Lancet. 2004;363:1892–1894
  19. Wise A, Foord SM, Fraser NJ. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2004;278:9869–9874
  20. Arner P, Goldinger M, Marcus C, Engfeldt P. Effects of lipolytic and antilipolytic agents on glucose transport in human fat cells. Int J Obes. 1991;15:327–331
  21. Flint DJ, Gardner MJ. Effects of cell volume on insulin binding, internalization and degradation in rat adipocytes. Mol Cell Endocrinol. 1984;36:229–236
  22. Blüher M, Wilson-Fritch L, Leszyk J, Laustsen PG, Corvera S, Kahn CR. Role of insulin action and cell size on protein expression patterns in adipocytes. J Biol Chem. 2004;279:31902–31909
  23. Blüher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell. 2002;3:25–38
  24. Weyer C, Wolford JK, Hanson RL, et al. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab. 2001;72:231–238
  25. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature. 2008;453:783–787
  26. James DE, Burleigh KM, Kraegen EW. Time dependence of insulin action in muscle and adipose tissue in the rat in vivo. An increasing response in adipose tissue with time. Diabetes. 1985;34:1049–1054
  27. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2007;193(3):61–65
  28. Kahn SE, Beard JC, Schwartz MW, et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38:562–568
  29. Alvarsson M, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest. 1996;56:563–570
  30. Kelly JJ, Lawson JA, Campbell LV, et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens. 2000;14:567–572
  31. Poynten AM, Gan SK, Kriketos AD, et al. Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism. 2003;52:699–704
  32. Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism. 2008;57:404–409
  33. Mobbs CV, Makimura H. Block the FAS, lose the fat. Nat Med. 2002;8:335–336
  34. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000;288:2379–2381
  35. Kovacs P, Harper I, Hanson RL, Infante AM, Bogardus C, Tataranni PA. A novel missense substitution (Val1483Ile) in the fatty acid synthase gene (FAS) is associated with percentage of body fat and substrate oxidation rates in nondiabetic Pima Indians. Diabetes. 2004;53:1915–1919
  36. Körner A, Ma L, Franks PW, et al. Sex-specific effect of the Val1483Ile polymorphism in the fatty acid synthase gene (FAS) on body mass index and lipid profile in Caucasian children. Int J Obes (Lond). 2006;20:
  37. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrinol Rev. 2000;21:697–738
  38. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549–2557

PII: S0021-9150(08)00839-3

doi: 10.1016/j.atherosclerosis.2008.11.026

Atherosclerosis
Volume 205, Issue 1 , Pages 207-213 , July 2009

Article Tools

* Image Usage & Resolution